ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES 2013 GLOBAL HEALTHCARE CONFERENCE
GHENT, Belgium, 29 May 2013 - Ablynx [Euronext Brussels: ABLX] today announces it will present at the annual Jefferies 2013 Global Healthcare Conference in New York on Monday,
3rd June 2013 at 01:30 p.m. EST (07:30 p.m. CET).
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will provide an update on the Company's late-stage proprietary Nanobody® programmes, the Company's growth and partnering strategy and the outlook for the near term future.
The presentation will be webcast live and can be accessed on the day via the Ablynx website at www.ablynx.com. A replay of the webcast will be available on the Company's website for 30 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Thomson Reuters ONE